{"id":"W2500289888","doi":"10.1200/jco.2015.33.15_suppl.4507","title":"Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Chromophobe cell; Everolimus; Sunitinib; Clinical endpoint; Internal medicine; Hazard ratio; Oncology; Renal cell carcinoma; Progression-free survival; Randomized controlled trial; Clear cell; Urology; Confidence interval; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003627975,0.00117288,0.001583965,0.0002574997,0.0004359848,0.001121012,0.0006420889,0.001281754,0.008478682],"category_scores_gemma":[0.003049779,0.0004043895,0.001841855,0.0002373077,0.0006801076,0.0008756875,0.000484145,0.002421255,0.001098608],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007363099,"about_ca_system_score_gemma":0.001138331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005179567,"about_ca_topic_score_gemma":0.001722718,"domain_scores_codex":[0.9987699,0.0007907888,0.00007159927,0.0001583494,0.00006611155,0.0001433163],"domain_scores_gemma":[0.9984928,0.0003697322,0.0003313977,0.0001280589,0.0001241632,0.0005537915],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9617451,0.005048151,0.001672959,0.0004172696,0.001588613,0.0000515874,0.00005511792,0.0006859954,0.001968125,0.0001737079,0.004153945,0.02243943],"study_design_scores_gemma":[0.9068202,0.08168714,0.005674919,0.00005955197,0.001238276,0.00009561938,0.00003031817,0.0004937963,0.000584068,0.0003832441,0.002913768,0.00001905094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9591908,0.00941208,0.00171141,0.002737385,0.000988783,0.006204451,0.007698579,0.0002080832,0.01184847],"genre_scores_gemma":[0.9797594,0.001530053,0.002025278,0.002229392,0.0003220602,0.00345679,0.006968332,0.00003879154,0.003670031],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008478682,"threshold_uncertainty_score":0.028364,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1607328342397249,"score_gpt":0.4422219842839687,"score_spread":0.2814891500442438,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}